Contact : +1 (888) 308-1808

/

Uncategorized

  • Setting expectations for treatment adherence in Duchenne care

    Edward Smith, MD, a neurologist, explains why setting clear expectations around treatment benefits and risks can help patients and families stay engaged with care plans over time. The post Setting expectations for treatment adherence in Duchenne care appeared first on Muscular Dystrophy News.

    Know More

  • Simply Stated: Introduction to CIAO1-Related Neuromuscular Disorder

    CIAO1-related neuromuscular disorder is an inherited condition that was first reported on in late 2023. It is caused by variants in the CIAO1 gene and primarily affects muscle function, though many affected people also experience problems with the nervous system. Much about the symptoms and progression of this newly discovered condition remains to be defined.…

    Know More

  • EU panel recommends expanded use of DMD treatment Agamree

    The Committee for Medicinal Products for Human Use (CHMP) has recommended that approval of Agamree (vamorolone) in the European Union be expanded to include people with Duchenne muscular dystrophy (DMD) as young as 2. The CHMP is an arm of the European Medicines Agency (EMA) tasked with reviewing data on experimental therapies. The committee’s recommendation…

    Know More

  • Advancing Duchenne Newborn Screening: A Collaborative Path Forward

    On April 24, 2026, PPMD, in collaboration with the Muscular Dystrophy Association (MDA) and the Little Hercules Foundation (LHF), convened a Duchenne Newborn Screening (NBS) Stakeholder Meeting in Philadelphia. The meeting’s main goal was to gather together industry partners in Duchenne to establish a foundation of understanding of the process of state implementation, and to…

    Know More

  • Expert Advice for Preparing for Medical Emergencies with NMD

    Julianne Meiser, MSS, LCSW, an Outpatient Social Worker in the Division of Neurology at the Children’s Hospital of Philadelphia. By nature, medical emergencies are unexpected, stressful, and often traumatic experiences. For those living with neuromuscular disease (NMD), seeking emergent medical attention due to an injury or illness carries additional layers of important considerations. Depending on…

    Know More

  • Starting corticosteroids earlier helps improve motor function in DMD

    Starting daily corticosteroids earlier in young children with Duchenne muscular dystrophy (DMD) helps them move better, walk or run faster, and keep their muscles stronger than delaying treatment by about one year, underscoring the importance of early diagnosis for preserving motor function. These are findings from a Phase 3 clinical study called FOR-DMD (NCT01603407), which…

    Know More

  • A tribute to a friend who taught us how to love, lead, and show up for others

    Last Saturday, I lost a dear friend of mine, Timothy Chan, who had Duchenne muscular dystrophy. He passed away in the hospital in the morning, days after he had been admitted with a respiratory illness. The unexpected news from his parents shocked me, as I had caught up with him and a few friends from…

    Know More

  • Patient-led group launches network of clinics to improve LGMD care

    Patient-led nonprofit The Speak Foundation has announced the launch of the LGMD Centers of Excellence, a novel alliance of clinics dedicated to improving care for people affected by limb-girdle muscular dystrophy (LGMD). “LGMD has historically faced significant barriers to therapeutic development due to fragmented care infrastructure and extremely small patient populations,” Kat Bryant Knudson, founder…

    Know More

  • Clinical Research Alert: Phase 3 Study of Omaveloxolone in Children and Teenagers with Friedreich Ataxia (FA)

    Researchers at Biogen are seeking pediatric FA patients to participate in a phase 3 clinical trial to better understand Friedreich ataxia (FA) and to evaluate omaveloxolone, an investigational therapy for children and teenagers with FA. The study  Children and teenagers with FA who are 2 to 15 years old may be eligible to participate in…

    Know More

  • Navigating disability benefits for muscular dystrophy

    When the progressive muscle weakness of muscular dystrophy (MD) begins to interfere with your employment, the transition can feel overwhelming, but it doesn’t have to mean a loss of financial independence. Securing public disability benefits can provide the vital financial assistance and medical coverage needed to manage life with MD. By understanding how the condition…

    Know More